In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas

被引：48

作者：

Bébéar, CM

Renaudin, H

Boudjadja, A

Bébéar, C

机构：

[1] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France

[2] Bayer Pharma, F-92807 Puteaux, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1998年 / 42卷 / 03期

关键词：

D O I：

10.1128/AAC.42.3.703

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 mu g/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. The minimal bactericidal concentrations of BAY 12-8039 increased only two-to eightfold compared to the MICs. Furthermore, they were comparable to those of sparfloxacin and lower than those of doxycycline and clarithromycin.

引用

页码：703 / 704

页数：2

共 9 条

[1] Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes
Aldridge, KE
Ashcraft, DS
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) : 709 - 711
[2] BEBEAR C, 1985, PATHOL BIOL, V33, P577
[3] Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones
Bebear, CM
Bove, JM
Bebear, C
Renaudin, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) : 269 - 273
[4] IN-VITRO AND IN-VIVO ACTIVITIES OF SPARFLOXACIN AGAINST MYCOPLASMA-PNEUMONIAE
KAKU, M
ISHIDA, K
IRIFUNE, K
MIZUKANE, R
TAKEMURA, H
YOSHIDA, R
TANAKA, H
USUI, T
TOMONO, K
SUYAMA, N
KOGA, H
KOHNO, S
HARA, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) : 738 - 741
[5] Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219)
Kenny, GE
Cartwright, FD
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) : 1048 - 1049
[6] SUSCEPTIBILITIES OF MYCOPLASMA-HOMINIS, MYCOPLASMA-PNEUMONIAE, AND UREAPLASMA-UREALYTICUM TO A NEW QUINOLONE, OPC 17116
KENNY, GE
CARTWRIGHT, FD
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) : 1726 - 1727
[7] Renaudin H, 1995, Drugs, V49 Suppl 2, P243
[8] INVITRO SUSCEPTIBILITIES OF MYCOPLASMA-PNEUMONIAE, MYCOPLASMA-HOMINIS, AND UREAPLASMA-UREALYTICUM TO SPARFLOXACIN AND PD-127391
WAITES, KB
DUFFY, LB
SCHMID, T
CRABB, D
PATE, MS
CASSELL, GH
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1181 - 1185
[9] In vitro activity of BAY 12-8039, a new fluoroquinolone
Woodcock, JM
Andrews, JM
Boswell, FJ
Brenwald, NP
Wise, R
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) : 101 - 106

← 1 →